Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 14/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4056700 | 0.89 | NAAA (0.56) | SLC6A9LMNATSHRNAAAKCNH2 | |
| SCHEMBL1378792 | 0.85 | SLC6A9 (0.55) | SLC6A9LMNATSHRNAAAHTT | |
| SCHEMBL4059873 | 0.82 | SLC6A9 (0.59) | SLC6A9KCNH2SMN1; SMN2SLC6A5 | |
| SCHEMBL1381763 | 0.81 | SLC6A9 (0.61) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL4056903 | 0.80 | SLC6A9 (0.62) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL4059565 | 0.78 | SLC6A9 (0.53) | SLC6A9NAAAKCNH2SLC6A5 | |
| SCHEMBL5040920 | 0.76 | SLC6A9 (0.71) | SLC6A9KCNH2 | |
| SCHEMBL5040943 | 0.76 | SLC6A9 (0.67) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL5037804 | 0.76 | SLC6A9 (0.68) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL3155206 | 0.76 | TSHR (0.52) | SLC6A9TSHRKCNH2HTTSLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828154-B1 | PHENYL-PIPERAZIN METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-7429585-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429585-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429585-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE (US) | 2008-09-30 | — | — | US | disclosed |
| US-20070219207-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | JOLIDON SYNESE | 2007-09-20 | — | — | US | disclosed |
| US-20070219207-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | JOLIDON SYNESE | 2007-09-20 | — | — | US | disclosed |
| US-20070219207-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | JOLIDON SYNESE | 2007-09-20 | — | — | US | disclosed |
| US-7241761-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241761-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241761-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060128712-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | US | disclosed |
| WO-2006061135-A1 | PHENYL-PIPERAZIN METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219207-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | GRIK5, GRM5, GRIN2C | SLC6A9 2292/4885LMNA 3065/4885TSHR 796/4885 |
| US-20060128712-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HTR5A, NPY5R, GRM5 | SLC6A9 4053/4885LMNA 2958/4885TSHR 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.